C. Alhan

发表

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

M. Cazzola, A. Órfão, V. V. D. van der Velden, 2012, Leukemia & lymphoma.

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.

G. Ossenkoppele, C. Eeltink, A. A. van de Loosdrecht, 2010, Blood.

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group

A. Órfão, V. V. D. van der Velden, J. te Marvelde, 2021, Cytometry. Part B, Clinical cytometry.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

E. Vellenga, J. Jansen, G. Ossenkoppele, 2017, Genes, chromosomes & cancer.

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

G. Ossenkoppele, A. A. van de Loosdrecht, P. Poddighe, 2016, European journal of cancer.

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

G. Ossenkoppele, A. A. van de Loosdrecht, T. Westers, 2015, Best practice & research. Clinical haematology.

Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype

J. Jansen, D. Chitu, A. A. van de Loosdrecht, 2021, British journal of haematology.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

V. V. D. van der Velden, J. te Marvelde, E. Vellenga, 2017, Haematologica.

Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations

G. Ossenkoppele, A. A. van de Loosdrecht, T. Westers, 2016, Cytometry. Part B, Clinical cytometry.

Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome

L. Nilsson, A. Porwit, D. Subirá, 2021, Annals of Hematology.

Quantitative Dynamics of Flow Cytometric Aberrancies during Treatment with Erythropoietin/G-CSF Are Predictive for Responses in LOW/INT-I Risk Myelodysplastic Syndromes.

G. Ossenkoppele, T. Westers, C. Alhan, 2008 .

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Wolfgang Kern, Jean Feuillard, Luca Malcovati, 2009, Haematologica.

Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.

V. V. D. van der Velden, J. te Marvelde, A. A. van de Loosdrecht, 2012, Leukemia research.

Do peripheral blasts count in myelodysplastic syndromes?

G. Ossenkoppele, A. A. van de Loosdrecht, T. Westers, 2009, Leukemia research.

P-095 A five parameter based flow cytometric scoring system refines the revised International Prognostic Scoring System for myelodysplastic syndromes

G. Ossenkoppele, T. Westers, C. Alhan, 2013 .

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

E. Vellenga, A. A. van de Loosdrecht, G. Huls, 2013, Leukemia research.

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program

E. Vellenga, B. Biemond, G. Huls, 2011 .

Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program

G. Ossenkoppele, M. Kappers-Klunne, G. Veth, 2013, Leukemia & lymphoma.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

G. Ossenkoppele, C. Eeltink, A. A. van de Loosdrecht, 2014, Cytometry. Part B, Clinical cytometry.

Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients

G. Ossenkoppele, C. Eeltink, T. Westers, 2010 .

Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.

G. Ossenkoppele, H. Bontkes, A. A. van de Loosdrecht, 2012, Leukemia research.

zacitidine differentially affects CD 4 pos T-cell polarization in vitro and in vivo in igh risk myelodysplastic syndromes

G. Ossenkoppele, T. Westers, C. Alhan, 2012 .

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

A. Órfão, V. V. D. van der Velden, J. te Marvelde, 2022, Cytometry. Part B, Clinical cytometry.

Dysplasia and PNH‐type cells in bone marrow aspirates of myelodysplastic syndromes

D. Chitu, A. A. van de Loosdrecht, T. Westers, 2021, Cytometry. Part B, Clinical cytometry.

Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy

G. Ossenkoppele, H. Bontkes, A. A. van de Loosdrecht, 2011, British journal of haematology.

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system

G. Ossenkoppele, B. Witte, T. Westers, 2016, Leukemia.

Flow Cytometry in Myelodysplastic Syndromes

G. Ossenkoppele, T. Westers, C. Alhan, 2011 .

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study

C. Pascutto, P. Vyas, L. Saft, 2012, Haematologica.

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

A. Órfão, G. Mufti, U. Johansson, 2012, Leukemia.

Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet

A. Órfão, V. V. D. van der Velden, J. te Marvelde, 2021, Cytometry. Part B, Clinical cytometry.

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes

G. Ossenkoppele, B. Witte, T. Westers, 2014, British journal of haematology.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes

G. Ossenkoppele, C. Eeltink, A. A. van de Loosdrecht, 2014, Cytometry. Part B, Clinical cytometry.

Validation of a Flow Cytometric Scoring System for the Prognostication of the Myelodysplastic Syndromes: a Retrospective Cohort Study

G. Ossenkoppele, T. Westers, C. Alhan, 2010 .

Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.

J. Tchinda, A. Jauch, M. Grez, 2015, Current gene therapy.

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

G. Huls, A. Beeker, N. Veeger, 2013, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.